INTRODUCTION 1 2
Next generation sequencing (NGS), Microarray hybridization (MH) and high throughput proteomic 3 techniques opened a new era in biomedicine by enabling large scale analysis of gene expression at 4 both the RNA and protein levels [Kumar, 2016] . Multiple experimental platforms based on different 5 principles and utilizing different reagents were developed for these tasks [Kumar, 2016] . According 6 to the International Aging Research Portfolio, over eight billion dollars in government funding have 7 been spent on research projects involving high throughput gene expression analysis since 1993 8 [Zhavoronkov, 2011] . This resulted in tens of thousands of publications. Unfortunately, gene 9 expression data obtained using different experimental platforms are poorly compatible with each 10 other even when obtained using the same biosamples. For example, a generally weak correlation 11 between NGS and microarray gene expression data has been reported [Buzdin, 2014] . Therefore, a 12 new data processing method is badly needed to enable data harmonization among different 13 platforms and experiments [MAQC Consortium, 2006; Zhang, 2013] . 14 1 containing different numbers of gene products [Haw, 2012; Nakaya et al., 2013] . Pathway 2 activation strength was also found to be a better marker of human tissue types [Borisov, 2014; 3 Lehznina, 2014] and tumor response to chemotherapy treatment [Zhu 2015; Venkova, 2015; 4 Artemov, 2015] . Several approaches were published by us and others to assess the activation of 5 signaling pathways, basing on large scale molecular data [Khatri, 2012; Buzdin, 2014b , 6 Zhavoronkov, 2014 . These methods take into account different factors like the extent of 7 differential gene expression, architecture of molecular pathways, and the roles of individual gene 8 products in a pathway (e.g., activator/repressor) [Khatri, 2012; Buzdin, 2014b] . For example, a 9 method we used to minimize discrepancies between the NGS and microarray platforms, termed 10
OncoFinder, relies on differential gene expression and the known roles in a pathway, but does not 11 take into account pathway architecture, i.e. the position of a gene product in a pathway [Buzdin, 12 2014b ]. 13
In spite of this progress it is not known why data aggregation improves expression information 14 stability and what factors influence it. It is also unclear which bioinformatic algorithms provide 15 better PAS outputs for cross-platform data stability. Additionally, PAS algorithms have not yet been 16 applied to the high throughput proteomic data . 17 In this study, we applied data aggregation methods to transcriptomic information obtained using 18 the Affymetrix HG U133 Plus 2.0, the Illumina HT12 bead array, the Agilent 1M array, the llumina 19
Genome Analyzer platforms, and to proteomic data from the Orbitrap Velos and XL mass 20 spectrometer platforms. We confirmed that for both transcriptomic and proteomic expression levels, 21
the PAS approach provided more stable results than the expression of individual genes. To explain 22 this phenomenon, we created a biomathematical model simulating error acquisition in individual 23 gene expression and in PAS-based approaches. In agreement with the experimental data, in the 24 mathematical model PAS methods produced significantly more stable results under a majority of 25 conditions. This model also predicts the optimal size of a molecular pathway and ideal parameters 26 of the normalizing (control) set of gene expression data. 1
To test the predictions further of the biomathematical model, we designed a new experimental 2 gene expression array using the CustomArray microchip platform (USA) enabling direct 3 electrochemical synthesis of oligonucleotide probes on a blank array. We compared results for the 4 seven human kidney cancer tissue samples independently profiled by the two laboratories on the 5 this customized array and on the commercial Illumina HT12 bead array platform. In agreement with 6 the theoretical model, gene expression features differed significantly among the platforms for the 7 same biosamples, while PAS values remained highly correlated. Therefore, gene expression data 8 aggregated at the PAS level appears to be the method of choice for cross-platform data comparisons, 9
including both transcriptomic and proteomic approaches. 10
We next explored the capacity of five most popular PAS calculation methods, OncoFinder 11 [Buzdin, 2014b] , TAPPA (Topology analysis of pathway phenotype association) [Gao, 2007] , 12
Topology-Based Score (TBScore) [Ibrahim, 2012] were tested. We also checked whether the PAS methods were able to retain biological features after 19 data harmonization using a generally accepted cross-platform harmonization procedure XPN 20 [Shabalin, 2008] . We found that the OncoFinder method showed the optimal performance in both 21 tests. 
Cross-platform processing of transcriptomic and proteomic data 3
We processed transcriptomic and proteomic data to establish pathway activation strength (PAS) 4 profiles corresponding to intracellular molecular pathways. The analysis included 271 molecular 5 pathways (Supplementary dataset S1). For PAS measurements, we applied the OncoFinder method 6 which was previously shown to diminish the cross-platform variation between the MH and NGS 7 data [Buzdin, 2014a] . OncoFinder has previously been applied to many human and non-human 8 systems including cell culture, leukemia and solid cancers, fibrosis, asthma, Hutchinson Gilford and 9
Age-Related Macular Degeneration Disease [Makarev, 2016; Artcibasova, 2016; Alexandorva, 10 2016; Lebedev, 2015] . The PAS for a given pathway (p) is calculated as: 
Building pathway activation profiles and assessment of batch effects 20
To identify if the OncoFinder technique may improve gene expression analysis by eliminating 21 batch effects, we profiled a set of human clinical bladder cancer tissue samples using the same 22 experimental platform (Illumina human HT 12 v4 bead arrays) in two different laboratories. We 23 investigated gene expression profiles generated from 17 bladder cancer samples and seven normal 24 bladder tissue samples. Eight cancer and four normal samples were analyzed in Dr. Kovalchuk's 25 laboratory in Lethbridge (Canada), and nine cancer and three normal bladder tissue samples were 26 analyzed in Dr. Buzdin's laboratory in Moscow (Russia). The gene expression data were deposited 1 in the GEO database (http://www.ncbi.nlm.nih.gov/geo/) with accession numbers GSE52519 and 2
GSE65635. 3
In agreement with previous reports [Lazar, 2013] , the normalized gene expression showed 4 significant batch effects with data from different laboratories clearly clustered on a Principal 5 Component Analysis (PCA) plot ( Fig.1A) . However, the PAS data formed a single merged cluster 6 ( Fig.1B) . The principle component variability was 4-6 times smaller for the PAS data ( Fig.1A,B ). 7
Similarly, using PAS values these two sets of samples formed mixed groups on a 8 hierarchical cluster heatmap (Fig.1C ). The Canadian samples were labeled 55 -72; the Russian 9 samples X1 -X8. Some sub-clusters are evidently formed by the samples coming from the different 10 sets, e.g. by samples X5, X8, 69, 68 and X1. (Fig.1C ). These data show that data aggregation at the 11 PAS level is sufficient to suppress the batch effect in gene expression comparisons. 12
13

Mathematical modeling of data aggregation effects 14
We investigated the hypothesis that the apparently higher robustness of OncoFinder PAS scoring 15 compared to single gene expression, is due to the cumulative nature of the former. PAS is the sum 16 of multiple mathematical terms that correspond to each individual gene product participating in a 17 pathway. Model calculations showed that this cumulative effect is able to reduce stochastic noise. 18
In the model, we included 271 pathways with variable numbers of gene products. We 19 assumed that the expression level of every gene product could be measured using two different 20 methods, say X and Y, corresponding to different experimental platforms (e.g. MH and NGS). Each 21 method introduces errors into the determination of gene expression level, and these errors are 22 independent. A Monte Carlo trial was performed as follows: we simulated both biased CNR (with a 23 median value of 1.5) and unbiased CNR with a median value of 1. We explored both noisy and 24 exact expression profiling methods, to allow whether measurement procedures introduce errors in 25 the true expression values. The four scenarios of the stochastic simulations (labeled A to D) are 26 shown in Table 1 . 1 For each scenario, we calculated the benefit ratio g p C C R = , where C p and C g are the 2 correlation coefficients between the results obtained using methods X and Y, using pathway-based 3 (PAS), and individual gene product-based log CNR values, respectively. For each subset of genes in 4 a pathway, we performed 100 Monte Carlo stochastic simulations and then computed the mean 5 values of C p and C g using the R statistical package. The greater R>1, the higher the benefit from 6
using PAS instead of individual gene expression for the cross-platform comparisons; R<1 means 7 operating at the individual gene product level is better than the PAS level. 8
For biased expression profiles, scenarios A and B of Table 1, (Fig. 2) , the PAS method 9
shows much better agreement between the results obtained using different methods, compared to 10 the individual gene expression levels. The data aggregation advantage of PAS is especially strong 11 when both expression methods are noisy (scenario A). In scenario B, when one method is exact, the 12 benefit of pathway data aggregation is lower. This is caused mainly by higher expression 13 correlation already at the level of individual gene products ( Fig. 3 ). However, the advantages of 14 PAS remain considerable for pathways that contain at least 10 gene products (Fig. 2 ). For shorter 15 pathways, the data aggregation effect is gradually decreased, and the R ratio reflecting the benefit of 16
using PAS values, trends towards 1. 17
For unbiased transcription profiles, with median relative gene expression levels equal to 1, 18 the data aggregation effect is completely lost (scenarios C and D). Here, the mean value for each 19 gene product component of the PAS score is zero; consequently, the expected PAS is also zero, and 20 the relative data variation is the same at the gene product and the PAS level. 21
The simulations clearly elucidate how the cumulative nature of PAS suppresses cross-22 platform data variation and batch effects. They show that there is a significant advantage of using 23 PAS to compare platforms, when at least one is noisy. This should apply to most if not all existing 24 high throughput experimental platforms, and it should be seen when experimental expression data is 25 compared. The simulations demonstrate that PAS calculations are advantageous for biased 26 transcriptomes and proteomes and virtually useless for unbiased ones. Unbiased data sets are too 1 similar to the control group used as the reference to calculate CNR values. This means that the PAS 2 approach will be especially useful when the expression signature in the sample under study is very 3 different from that of the control samples. This finding may help to identify appropriate control 4 samples for decreasing expression data noise. Finally, this model shows that the higher is the 5 number of gene products in a pathway, the greater the benefit of shifting from individual 6 gene/protein expression to PAS data For example, the mean number of gene products in the 7
OncoFinder database is 68 per pathway, and the model predicts about a 4.5 -fold decrease in data 8 variation at the PAS level in the biased noisy-noisy scenario, which may explain the success of the 9
OncoFinder approach in various applications [Buzdin, 2014a] . 10 11
Experimental model of cross-platform comparisons. 12
In transcriptomic methods, batch effects arise from errors introduced at the stages of RNA 13 purification, library preparation and amplification, hybridization and reading of arrays [Risso, 14 2011 ]. We investigated whether the OncoFinder PAS algorithm can suppress batch effects 15 introduced by cross-platform comparisons. At the same time we assessed if the algorithm works 16 efficiently for formalin-fixed, paraffin-embedded (FFPE) tissue samples. Seven FFPE tissue blocks 17 isolated from human renal carcinomas were profiled using two independent experimental platforms. 18
The first was the Illumina HT 12 v4 bead array system optimized for FFPE tissues. The second was 19 a customized microchip system developed using the CustomArray (USA) technology of direct on-20 chip electrochemical oligonucleotide synthesis. The custom arrays had 3775 oligonucleotide probes 21 corresponding to 2214 human gene products involved in 271 intracellular signaling pathways 22
(Supplementary dataset S1). The custom arrays, used the original oligonucleotide probe sequences 23 of the Illumina HT 12 v4 platform, but shortened by 5 nucleotides at the 5' end and by 5 nucleotides 24 at the 3' end. Quantile -normalized gene expression data were deposited into the GEO database 25 with the accession numbers GSE65637 and GSE65639. The differences between the Illumina and 26 the Custom platforms included shorter oligonucleotide probe sequences, different library 1 preparation protocols and different hybridization signal development and reading methods 2 ( Supplementary Fig.1 ). The Custom method for library preparation was quite distinct from Illumina 3 and identical to that used by the Agilent MH platform ( Supplementary Fig.1B ,C,E) with the sole 4 exception that biotinylated rather than fluorescently labeled DNA is used at the terminal stage 5 ( Supplementary Fig.1 B,E) . A brief comparison of the protocols used for the Custom and top 6 commercial MH platforms manufactured by the Illumina, Agilent and Affymetrix companies for 7 FFPE tissue profiling is given in Supplementary dataset S2. 8
To compare with the renal carcinoma samples, we used GEO dataset GSE49972 [Karlsson, 9 2014 ] containing 6 normal kidney samples to normalize the expression data and calculate PAS. The 10 normalized CNR expression data and PAS values are shown in Supplementary dataset S1. At the 11 level of individual gene products, we observed relatively low correlations (0.2-0.3) between the 12 same transcriptomes profiled using the two platforms ( Fig. 4 ; Supplementary dataset S3). In 13 contrast, at the PAS level the correlations were strong, varying from 0.84 to 0.91 ( Fig. 4 ; 14
Supplementary dataset S3). 15
These results experimentally confirm the hypothesis that data aggregation at the PAS level 16 increases the stability of cross-platform expression data and that the advantage of PAS is retained 17 for FFPE samples. 18 19
Data aggregation effects assessed on different RNA and protein expression profiles 20
We investigated quantitative aspects of the effect of data aggregation on several datasets where the 21 same samples were profiled using different expression platforms (Tab. 2, Supplementary dataset 22 S4). 23 We observed two trends for the behavior of the benefit ratio . In model 24 calculations, we observed a crucial role of expression profile bias between the case and normal 25 samples for successful data aggregation of genes into pathways (Fig. 2, 3 ). We introduce a measure 26 of such bias, termed
σ are the mean and standard deviation, 1 respectively, of the set of log CNR values obtained for a given sample using the experimental 2 platform i. The results of the model calculation ( Fig. 2,3 , scenarios A and B) suggest that, even for 3 the same values of β, R may be different depending on C g (correlation at the individual gene 4 product level): the higher C g , the lower R at equal β.
5
With a discrimination threshold for C g chosen as equal to 0.25 between low-correlated and the 6 considerably correlated samples, we can see the clear clusters of data for data aggregation effect 7 ( Fig. 5 , blue dots for low and red dots for considerably correlated samples. Note that the two 8 clusters of data depending on the C g threshold are seen for both transcriptome-to-transcriptome and 9 transcriptome-to-proteome comparisons. 10
The data obtained suggests that when β is low, the R is hardly distinguishable from 1; 11 however, when β exceeds a threshold, the increase of R becomes statistically significant. Finally, 12 these results also demonstrate that transcriptomic and proteomic profiles demonstrate more 13 compatible results at the molecular pathway level rather than on the level of individual gene 14 products. 15 16 17
Comparison of PAS scoring methods according to their capacities in data aggregation 18 19 We compared the abilities of five popular PAS scoring methods to yield an advantageous 20 the data aggregation effect when the expression of molecular pathways is compared instead of 21 individual gene products. For the seven renal carcinoma samples discussed above, we calculated R 22 using alternative PAS scoring methods: OncoFinder [Buzdin, 2014b] , topology analysis of pathway 23 phenotype association, TAPPA [Gao, 2007] , topology-based score (TB) [Ibrahim, 2012] , pathway-24 express (PE) [Draghici, 2007] , and signaling pathway impact analysis (SPIA) [Tarca, 2009] 25 methods (Supplementary data set S5). These methods differ in the factors used to evaluate the 1 importance of distinct gene products in pathway activation. 2
Only three of the methods, OncoFinder, PE and SPIA, showed a substantial data aggregation 3 effect (R) ranging from 2-2.3. Other methods showed lack of any positive effect (Fig. 6 ). Cross-platform data comparison has the potential to become an extremely useful tool in 7 contemporary biomedicine and bioinformatics. Although the application of PAS methods has the 8 ability to restore correlations between different expression data sets, the absolute values of PAS may 9 differ between platforms. To overcome this inconsistency, several cross-platform harmonization 1 10 methods can be applied ranging from the simplest z-scaling and mean-centering to more 11 sophisticated algorithms utilizing machine-learning/Bayesian harmonization (e.g., [Warnat, 2005; 12 probability densities of the Euclidean distances between the PAS vectors calculated for the three 4 samples (B, C, and D) differ greatly depending on the PAS scoring method used (Fig.7) . In such an 5 assay, an ideal PAS scoring method should make distinctions between samples depending primarily 6 on the sample types, rather than on the experimental platform used. A satisfactory PAS calculation 7 method, therefore, should yield a unimodal distribution of the PAS-PAS distances, without any 8 significant deviations. If the distribution of PAS-PAS distances is bimodal or multimodal, this points 9
to the inability to eliminate platform-specific bias even at the pathway level. Only the OncoFinder 10 and TAPPA methods were able to eliminate the cross-platform bias for all three sample types 11 ( Fig.7) . 12
Hierarchical clustering (dendrograms shown in Supplementary data set S7). demonstrates 13 that only the OncoFinder and TAPPA methods enabled clustering of the PAS vectors exclusively 14 according to biological sample type. Thus, among the five PAS scoring algorithms tested, only 15
OncoFinder showed effective data aggregation with efficient retention of biological information in 16 three independent tests (Table 3) High throughput gene expression may produce both random and systematic errors, arising from the 21 steps in RNA or protein purification, library preparation and/or amplification, hybridization and 22 sequencing, reading arrays, and mapping and annotation of the reads [Chalaya, 2004; Shugay, 2014; 23 Risso, 2011] . It is generally hard to identify the types of errors and to find out which kind of 24 experimental protocol provides more reliable data. While the measured concentration of each 25 individual gene product may be in error, we show in this report that combining sufficient numbers 26 of these concentrations into a pathway-oriented network apparently generates significantly more 1 stable data. We also tested whether OncoFinder and other PAS scoring methods can improve 2 expression data to suppress batch effects, the unwanted variation in gene expression measurements 3 on the same experimental platform made at different times, which frequently originate from the 4 limitation in the number of samples that can be processed at once in a single experiment 5 [Demetrashvili, 2010] . Batch effects also hinder the combination of different experimental datasets. 6
Batch effects are almost inevitable [Lazar, 2012] . By limiting analyses to single data sets, one 7 frequently must use an insufficient number of samples, which leads to high false-negative rates 8 [Lazar, 2012] . Eliminating batch effects enables larger datasets, and provides more statistical 9
power to subsequent analyses [Lazar, 2012] . 10
Here, using the Illumina HT12 bead array platform to profile human cancer samples, we 11 demonstrate that the PAS scoring technology OncoFinder effectively suppresses batch effects 12 present in the individual gene expression measurements (Fig.1) . OncoFinder efficiently increases 13 expression data stability from all major experimental platforms, for both fresh and formalin-fixed, 14 paraffin-embedded tissue samples (Fig.4) . Discrepancies in data obtained on the same and different experimental platforms, rmust be 21 addressed by different methods, termed normalization and harmonization, respectively. For intra-22 platform normalization, more attention is paid to equilibration of scaling factors, while cross-23 platform harmonization must address the type of distribution of output intensities for each gene. 24
Exiting methods for intra-platform normalization include quantile normalization [Bolstad, 2003] involves data clustering and finding similarity regions among results obtained using different 6 platforms, to strengthen similarity during the harmonization process. 7
Unfortunately, current normalization and harmonization methods hardly distinguish between 8 artifacts introduced by batch effects and the real biological differences. Additional tools are needed 9
to improve normalization and harmonization procedures. We demonstrate here for most major 10 transcriptomic and proteomic commercial platforms that data aggregation at the level of molecular 11 pathways has the potential to reduce greatly the bias in the datasets under comparison. Since each 12 pathway may contain hundreds of different gene products, transition from single gene products to 13 the whole pathway level may restore biologically significant correlations. 14 We propose a term data aggregation effect for such restoration of biological correlation at 15 the pathway level. We created a mathematical model that simulates it and identifies the necessary 16 conditions for its applicability. Sample expression profiles must be biased compared to control 17 samples, i.e. the transcriptional signatures of the case samples must differ significantly from the 18 normal ones (Fig. 5 ). The strength of the data aggregation effect grows with the number of gene 19 products in a molecular pathway. The data aggregation effect is especially strong when the initial 20 correlation between the expression data is weak (Fig. 2,3) . Finally, the choice of PAS scoring 21 method affects the data aggregation effect. On a model data set, the OncoFinder, Pathway-Express 22 and SPIA algorithms result in a considerable data aggregation effect, while TAPPA and TB-Score 23 don't ( Fig. 6 ). Only OncoFinder and TAPPA were able to preserve the biological features on the 24 model dataset MAQC after cross-platform harmonization, while with Pathway-Express, SPIA and 25 TB-Score methods, platform-introduced bias features still dominated the output expression 26 signatures ( Fig.7) . Thus, among the five PAS scoring methods tested here, the OncoFinder 1 algorithm showed the best efficiency and accuracy (Tab.3), which makes OncoFinder a method of 2 choice for many applications using high-throughput analysis of gene expression at the RNA or 3 protein levels. 4
It should be possible in the future to refine PAS methods to create universal platform-5 agnostic analytic tools. These tools have a huge potential to accelerate progress in genetics, 6 physiology, biomedicine, molecular diagnostics and other applications by combining unbiased data 7 from many sources and various experimental platforms. 
Functional annotation of gene expression data 14
The SABiosciences (http://www.sabiosciences.com/pathwaycentral.php) signaling pathways 15 knowledge base was used to determine structures of intracellular pathways, as described previously 16 [Spirin, 2014] . 17
OncoFinder. We applied the original OncoFinder algorithm [Buzdin, 2014b] for functional 18 annotation of the primary expression data and for calculating PAS scores. The microarray gene 19 expression data were quantile normalized according to [Bolstad, 2003] . The formula used to 20 calculate the PAS for a given sample and a given pathway p is as follows: 21
Here the case-to-normal ratio, CNR n , is the ratio of the expression level of gene n in the sample 23 under investigation to the average expression level of that gene in the control group of samples. The 24
Boolean flag of BTIF (beyond tolerance interval flag) equals one or zero when the CNR value has 25 simultaneously passed or not passed, respectively, the two criteria that indicate a significantly 1 perturbed expression level from an essentially normal expression level. The first criterion is that the 2 expression level of the sample lies within the tolerance interval, with p < 0.05. The second criterion 3 is whether the CNR value lies outside the cut-off limits, i.e., either CNR < 2/3 or CNR > 3/2. ARR np , 4 the discrete value of the activator/repressor role equals the following fixed values: −1, when the 5 gene/protein n is a repressor of molecular pathway; 1, if the gene/protein n is an activator of 6 pathway; 0, when the gene/protein n is known to be both an activator and a repressor of the 7 pathway; and 0.5 and −0.5, respectively, tends to be an activator or a repressor of the pathway p, 8 respectively. 9
Our approach to calculations of РAS implies two principal assumptions: 10 1) First, computational modeling of signal transduction processes [Birtwistle, 2007; Borisov, 2009; 11 Kuzmina, 2011] indicates that for most interacting proteins the concentration of their active forms, 12 which are sufficient for downstream signaling, is much lower than the total abundance of the 13 corresponding protein. In other words, signal transduction may be performed even at the very low 14 level for most gene products. 15
2) Second, we stipulate that each pathway graph may be simplified up to the following structure 16 that includes only two chain-like (linear) branches: one for sequential events that promote activation 17 of whole pathway, and another for repressor sequential events. The adequacy of this quite radical 18 approximation was shown before in comparison with the full-scaled kinetic model [Kuzmina, 19 2011 ], when all protein-protein interactions were described using the mass-action law along each 20 edge of a highly branched pathway graph [Buzdin, 2014] . 21
Under these conditions, we presume that all activator/repressor members have equal importance for 22 the whole pathway, and come to the following formula for the overall signal outcome (SO) of a 23
given pathway, activator (i) and repressor (j) members, respectively. To obtain an additive value, it is possible to 1 take the logarithmic levels of gene expression, and thus come to a function of PAS. 2
The results for 271 pathways were obtained for each sample (see Supplementary Data set S1). 3
Statistical tests used the R software package. 4
TAPPA (Topology analysis of pathway phenotype association). Imagine а pathway graph,
is the set of graph nodes (vertices), and 6 } interact and genes | ) ,
is the set of graph edges [Gao, 2007] . The adjacency 7 matrix is defined as follows,
Z-scoring procedure was applied to the logarithmic gene expression matrix s orig is orig is is
The adjacency index for a pathway is defined as follows, 10
where N is the number of genes in the pathway, and the double summation of over the 12 ) ( sign TBScore (Topology-based score) [Ibrahim, 2012] . For a pathway p that has N nodes, the value 18 non-differential genes, or equals to the sum of log-fold-changes of the differential genes in the node 20
i . The gene is considered differential, if the gene is considered differential in terms of the Boolean 21 flag BTIF (as for the OncoFinder algorithm). The node weight, NW i , equals the number of 22 downstream nodes for node i. To determine the value of NW i , we used the depth-first search 23 method [Even, Sh. Graph Algorithms, Cambridge University Press, 2011] using labeling visited 1 nodes to avoid the infinite cycling. 2 Pathway-Express (PE) [Draghici, 2007] . The PE-score for a pathway K was calculated as follows, 3
The first term in this sum is the p-value for the probability to obtain the observed or a higher The search for upstream/downstream genes is performed according to the depth-first search method, 16
as in the TBScore method. 17 SPIA (Signal pathway impact analysis) [Tarca, 2009] . To obtain an estimator for pathway 18 perturbation that is positive for an up-regulated and negative for a down-regulated pathway, use the 19 second term in formula (4), resulting in the accuracy value,
It can be 20
shown that [Tarca, 2009] this accuracy vector may be expressed as follows, 21 
The overall score for pathway pertubation calculated as:
Statistical tests 6
Principal component analyses were performed using the MADE4 package [Culhane, 2005] . 7
Hierarchical clustering heat maps with Pearson distances and average linkage were generated using 8 heatmap.2 function from the gplots package [Scales, 2015] . 9
Mathematical modeling 11
We performed a Monte Carlo trial to investigate the data aggregation effect. Something may be 12 missing here? We assumed that the number of genes in each pathway is distributed log-normally 13 with the variable median number N. The case-to-normal-ratio (CNR) values for each gene were also 14 sampled from the log-normal law, so that the value of log CNR had a normal distribution. When 15 sampling CNR, we distinguished between biased and unbiased models of gene expression. For the 16 biased model, the CNR distribution has a median value of 1.5, whereas for the unbiased model, the 17 median CNR value is 1. The standard deviation of the mean log CNR value was set to 0.3 for both 18 biased and unbiased models. The independent error produced by an experimental platform was also 19 sampled stochastically. We simulated both the exact and noisy expression profiling methods. By the 20 definition, exact methods did not introduce errors. For noisy methods, the error was chosen from 1 the log-normal distribution, with a median value of 1.0. All the calculations were made using the R 2 open source platform (version 3.1.2). 3 4
Analysis of published transcriptomic and proteomic datasets 5
Prior to analysis, all the microarray data were quantile normalized [Bolstad, 2003] , and the RNA-6 seq data were normalized using the DESeq package from Bioconductor software [Anders, 2010]. 7
All gene products showing zero intensities were skipped to avoid aberrant data variations. Pearson 8 correlation coefficients between the same samples examined using different expression profiling 9 methods (e.g., proteome vs transcriptome or MH vs NGS) were calculated at two levels of data 10 aggregation: first, at the level of distinct genes and gene products -namely for the value of log CNR 11 (the so-called C g correlation value); and, second, at the level of the whole pathways, for the PAS 12 value (the C p correlation coefficient). Then, the ratio (magenta)unbiased expression exact method Y. The method X is always condsidered noisy. The C g threshold between the samples low and considerably correlated at the gp level was chosen as 5 equal to 0.25; blue dots: low correlation at gene product level; red dots: considerable correlation at 6 gene product level. unimodal distribution indicates lack of significant difference between within-platform and cross-4 platform distances. A bimodal distribution means that the cross-platform PAS distance (upper mode 5 in the violin plots) is essentially higher that the within-platform distance. See text for descriptions 6 of the different scoring methods. 7
